Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 6 years of Current Deferred Revenue data on record, last reported at $288000.0 in Q2 2025.

  • For Q2 2025, Current Deferred Revenue changed 0.0% year-over-year to $288000.0; the TTM value through Jun 2025 reached $288000.0, changed 0.0%, while the annual FY2024 figure was $288000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $288000.0 in Q2 2025 per VRDN's latest filing, roughly flat from $288000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $289000.0 in Q4 2021 and bottomed at $288000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $288058.8, with a median of $288000.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: decreased 3.99% in 2021, then changed 0.0% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $289000.0 in 2021, then dropped by 0.35% to $288000.0 in 2022, then changed by 0.0% to $288000.0 in 2023, then changed by 0.0% to $288000.0 in 2024, then changed by 0.0% to $288000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $288000.0 in Q2 2025, $288000.0 in Q1 2025, and $288000.0 in Q4 2024.